Allianz Asset Management GmbH Boosts Stock Position in Integra LifeSciences Holdings Corporation $IART

Allianz Asset Management GmbH increased its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 88.7% during the third quarter, according to its most recent filing with the SEC. The fund owned 433,738 shares of the life sciences company’s stock after buying an additional 203,834 shares during the quarter. Allianz Asset Management GmbH owned 0.56% of Integra LifeSciences worth $6,215,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of IART. Rubric Capital Management LP grew its holdings in Integra LifeSciences by 58.4% during the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after purchasing an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY lifted its position in shares of Integra LifeSciences by 57.5% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after buying an additional 796,300 shares during the last quarter. Access Investment Management LLC bought a new position in shares of Integra LifeSciences during the 2nd quarter worth $5,348,000. Soleus Capital Management L.P. increased its holdings in Integra LifeSciences by 29.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock worth $17,029,000 after acquiring an additional 315,614 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Integra LifeSciences in the 2nd quarter valued at about $2,960,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Down 2.9%

Integra LifeSciences stock opened at $10.93 on Tuesday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14. Integra LifeSciences Holdings Corporation has a fifty-two week low of $10.65 and a fifty-two week high of $25.95. The stock has a market cap of $851.34 million, a P/E ratio of -1.69 and a beta of 1.04. The firm’s fifty day moving average price is $12.46 and its 200-day moving average price is $13.32.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Citigroup cut their target price on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research report on Friday, October 31st. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Truist Financial reiterated a “hold” rating and issued a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. JPMorgan Chase & Co. increased their target price on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $15.00.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.